Browsing Tag
RC220
3 posts
Racura Oncology (ASX:RAC): Will HARNESS-1 reset its valuation?
Racura Oncology has funded three cancer trials, but RAC shares remain far below their high. HARNESS-1 must now turn clinical progress into evidence.
Racura Oncology (ASX:RAC) funds three cancer trials, but can RC220 justify the valuation?
Racura Oncology has funded three RC220 trials, but valuation now depends on clinical proof. Can ASX:RAC turn capital into decisive cancer data?
Racura Oncology (ASX: RAC) stock up 12.21% as MYC silencing data builds case for bisantrene relaunch
MYC is the undruggable cancer gene. Racura Oncology (ASX: RAC) says bisantrene silences it via G4 stabilisation. Three clinical trials, A$19m cash, and a 2027 inflection ahead.